AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

Te Awa Lakes a good fast-track candidate
Property

Maria Slade: Te Awa Lakes a good fast-track candidate

Explanation of why some other projects made the list would be helpful.

Dual-listed retailers kick off 2025 with mixed results
Retail

Dual-listed retailers kick off 2025 with mixed results

KMD Brands and Michael Hill both reported lower-than-expected earnings guidance.

Why LIC is revisiting its strategy
Primary Sector

Why LIC is revisiting its strategy

Genetics company says its diagnostics arm is showing 'really strong' growth.